Refine by
Post Surgery Articles & Analysis
73 news found
Planning brain surgery is a delicate process that requires precision to avoid damaging surrounding brain tissue and to prevent post-surgery complications. ...
In the realm of pulmonary research, the search to understand complex lung conditions has led to the development of various animal models. Among these, a new murine model from Tsijis et al stands out for its potential to investigate flow-induced pulmonary hypertension (PH) and compensatory lung growth (CLG). This blog outlines this innovative model, its significance, and the method of ...
Instylla is now enrolling patients in a clinical trial for the world’s first hydrogel-based liquid embolic intended for the treatment of hypervascular tumors. A second initial application for its Embrace embolic therapy is hemorrhage control, where the product offers advantages in terms of simplicity, speed, and safety. Amar Sawhney and his teams, it seems, can make medical hydrogels do ...
Highlights Discussions held with US and EU Regulators and Clinical Key Opinion Leaders Proposing two Phase 3 studies in two major surgery types to aim to provide a broad surgery label for XF-73 Nasal Phase 3 programme will deliver an approvable data package for both US and EU authorities. ...
XF-73 XF-73 Nasal is a novel drug being developed by Destiny Pharma to eradicate S. aureus (SA), including MRSA from the nose before surgery to prevent post-surgical infection. The use of this simple nasal gel before surgery will reduce the need for antibiotic decolonization and by reducing post-surgical infection it will also ...
Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce the commencement of an Investigational New Drug (IND) enabling safety study with its novel XF-73 Dermal formulation. This study is the second of two planned preclinical safety studies of the XF-73 ...
“Glioblastoma remains one of the most aggressive and difficult to treat cancers globally and we believe that targeted radiotherapy and particularly ITM-31 can make a significant impact for patients by selectively eliminating tumor remnants post-surgery,” said Steffen Schuster, CEO of ITM. “Based on the promising preclinical data we have seen to ...
Aatru Medical, LLC ("Aatru") today announced U.S. Food and Drug Administration (FDA) 510(k) Class II clearance of the NPSIMS™ Negative Pressure Surgical Incision Management System. The NPSIMS utilizes an innovative mode-of-action that eliminates the expensive electromechanical pump, battery, and electronics found in most other negative pressure wound therapy (NPWT) systems being deployed ...
Key potential benefits cited in the BDD application include less invasive and shorter surgery, improved intra- and post-operative outcomes, reduction or elimination of hospitalization length of stay, and improved patient quality of life, including motion-preservation at the affected spinal level. "Our receipt of the Breakthrough Device Designation is a welcome ...
Recruited patients undergo a pre-surgery nasal culture to determine the prevalence of Staphylococcus aureus, the main cause of surgical site infections. Each patient then receives Ondine’s nasal photodisinfection (investigational product) followed by a post-treatment culture, enabling evaluation of the efficacy of nasal photodisinfection across a wide ...
Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening acute respiratory and critical care conditions, including drug overdose, post-surgery respiratory depression, and apnea of prematurity. The Company retains all global rights to ENA001 and plans to initiate ...
Food & Drug Administration (“FDA”) to market its first product, a fluorescence guided surgery (FGS) system. The OnLume Imaging System is indicated for fluorescence imaging of blood flow and tissue perfusion before, during, and after vascular, gastrointestinal, organ transplant, plastic, reconstructive, and micro surgeries. This intraoperative ...
"We believe ENA001 has the potential to significantly improve the standard of care for many patients experiencing life-threatening respiratory depression, including those due to drug overdose, post-operative conditions, and apnea of prematurity. We believe the results of this study further highlight the profile of ENA001 as a potentially effective and safe agnostic respiratory ...
LB1148 is an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. In a previously conducted Phase 2 trial in gastrointestinal (GI) surgery, Palisade Bio and Newsoara demonstrated LB1148 had a statistically significant (p=0.0008) effect in accelerating ...
About LB1148 LB1148 is a novel oral liquid formulation of the well-characterized digestive enzyme inhibitor, tranexamic acid (“TXA”), with potential to both reduce abdominal adhesions and help restore bowel function following surgery. The therapy is being developed for administration prior to major surgeries that are at risk of disrupting the ...
The scaffold is temporary and, after a few months, is removed using a bronchoscope (a minimally invasive procedure, there is no second surgery in the chest), leaving behind a regenerated bronchus derived from the patient's own cells. ...
Recent Business Highlights Generated 2021 total revenue of $49.0 million, an increase of 77% compared to the prior year Generated fourth quarter 2021 total revenue of $14.7 million, an increase of 63% compared to the prior year period Expanded total gross margin to 87% in the fourth quarter 2021 versus 74% in the prior year period Received FDA 510(k) Clearance of the TearCare® System ...
” Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN) assessed the efficacy of LB1148 to reduce the formation of adhesions in subjects undergoing abdominal surgery. Study LBS-IST-POI-101 was a Phase 1, single-center, open-label, study enrolling 11 subjects undergoing GI surgery. ...
There simply aren’t many treatment options for knee pain outside pain management and, eventually, surgeries.” Continued Laflamme, “Our partnership with The Geneva Foundation is incredibly valuable, and the grant support from the Quebec Ministry of Economy and Innovation allows us to bring our solutions into military clinics. ...
ByEmovi
ABFT aims to support injured players in need with the cost of medical treatment, doctors, surgeries and rehabilitation facilities to recover from sport injuries and carry on with their career. Healthium will provide its arthroscopy implants required for the surgeries free of cost. In sports, players often face injuries during their career. ...